ERGO logo

Ergomed plc Stock Price

AIM:ERGO Community·UK£701.1m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

ERGO Share Price Performance

UK£0
0.00 (0.00%)
UK£0
0.00 (0.00%)
Price UK£0

ERGO Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

2 Risks
2 Rewards

Ergomed plc Key Details

UK£152.1m

Revenue

UK£68.8m

Cost of Revenue

UK£83.3m

Gross Profit

UK£68.3m

Other Expenses

UK£15.0m

Earnings

Last Reported Earnings
Jun 30, 2023
Next Reporting Earnings
n/a
0.29
54.75%
9.86%
0%
View Full Analysis

About ERGO

Founded
1997
Employees
1400
CEO
n/a
WebsiteView website
www.ergomedplc.com

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

Recent ERGO News & Updates

Recent updates

No updates